Wellgistics Health, Inc. (“Wellgistics” or the “Company”) (NASDAQ:WGRX) announces that it has entered into a non-exclusive, non-binding Letter of Intent (“LOI”) to evaluate a potential acquisition of Neuritek Therapeutics, a neuroscience-focused research organization. Neuritek Therapeutics Inc. has developed a next-generation bio-mechanism based treatment, treating the root cause of Post-Traumatic Stress Disorder (PTSD). Neuritek’s first to market treatment is an orally active inhibitor of fatty acid amide hydrolase type 1 (FAAH1), the enzyme responsible for metabolizing anandamide (AEA) and the first mechanisms-based treatment for PTSD.
Read the full article: Wellgistics Health Inc. Signs $105M Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. //
Source: https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/wellgistics-health-inc.-signs-105-000-000-letter-of-intent-to-evaluat-1150528